Compare ENGN & SUNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ENGN | SUNS |
|---|---|---|
| Founded | 1999 | 2023 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Real Estate Investment Trusts |
| Sector | | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.2M | 108.7M |
| IPO Year | 2023 | 2024 |
| Metric | ENGN | SUNS |
|---|---|---|
| Price | $1.72 | $7.90 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 1 |
| Target Price | ★ $21.08 | $8.75 |
| AVG Volume (30 Days) | ★ 665.6K | 79.6K |
| Earning Date | 06-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | ★ 16.17% |
| EPS Growth | ★ 56.85 | N/A |
| EPS | N/A | ★ 0.54 |
| Revenue | N/A | ★ $21,571,434.00 |
| Revenue This Year | N/A | $70.81 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $14.37 |
| Revenue Growth | N/A | ★ 102.96 |
| 52 Week Low | $1.40 | $7.34 |
| 52 Week High | $12.25 | $11.78 |
| Indicator | ENGN | SUNS |
|---|---|---|
| Relative Strength Index (RSI) | 42.90 | 45.73 |
| Support Level | $1.68 | $7.39 |
| Resistance Level | $1.84 | $8.18 |
| Average True Range (ATR) | 0.07 | 0.25 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 39.26 | 55.00 |
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.
Sunrise Realty Trust Inc is a real estate investment trust company. It is focus on originating CRE debt investments and providing capital to high-quality borrowers and sponsors with transitional business plans collateralized by CRE assets with opportunities for near-term value creation, as well as recapitalization opportunities. It intends to create a diversified investment portfolio, targeting investments in senior mortgage loans, mezzanine loans, whole loans, B-notes, CMBS, and debt-like preferred equity securities across CRE asset classes and investment mix to include high-quality multi-family, condominiums, retail, office, hospitality, industrial, mixed-use, and specialty-use real estate. The company's portfolio is concentrated in the Southern U.S.